Our comprehensive panel-based approach evaluates specific antibodies which have been associated with autoimmune or paraneoplastic axonal neuropathies. Because of the overlap of clinical symptoms, we recommend a panel-based approach rather than individual antibody testing.
Divyanshu Dubey, M.B.B.S. gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
AIAES - Autoimmune Axonal Evaluation, Serum (Mayo ID: AIAES)
Identifying neuropathies with an immune mediated etiology, which are likely to respond to immunotherapies.
Serological evaluation of patients who present with a subacute neurological disorder of undetermined etiology, especially those with known risk factors for cancer.
Directing a focused search for cancer.
Investigating neurological symptoms that appear in the course of, or after, cancer therapy, and are not explainable by metastasis.
Differentiating autoimmune axonal neuropathies from neurotoxic effects of chemotherapy.
Detecting early evidence of cancer recurrence in previously seropositive patients.
Specimen Type: Blood
Container/Tube: Red Top
Acceptable: Serum gel
Specimen Volume: 5 mL
Monday through Friday; Varies